Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

Reporte de Evento Adverso o Queja de Producto 

Información médica

Are you prescribing in line with treatment guidelines for your mild to moderate inflammatory acne patients?

Go to Close Top

Web

EDF S3-Guideline for the treatment of acne (Updated 2016):

  • Highest recommendation for fixed-dose combinations of Benzoyl Peroxide (BPO) + clindamycin (Duac) or BPO + adapalene as first-line therapy for the treatment of mild to moderate papulopustular acne 1
  • Recommends against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance 1

Find out more

Web

AAD Guidelines of care for the management of acne vulgaris (Updated 2016):

  • Recommend combinations of topical antibiotics and benzoyl peroxide as a first line therapy in mild to moderate acne patients (Class A recommendation, Level I evidence) 2
  • Recommend against the use of topical antibiotic monotherapies to reduce the development of antibiotic resistance 2

Find out more

References:

  1. Nast A et al. JEADV 2016;30(8):1261–1268.
  2. Zaenglein AL et al. J Am Acad Dermatol 2016;74(5):945–973.e33.

Duac is a registered trademark of Stiefel, a GSK company.